Format

Send to

Choose Destination
Br J Haematol. 2019 May 1. doi: 10.1111/bjh.15923. [Epub ahead of print]

Multicentre retrospective study of intravascular large B-cell lymphoma treated at academic institutions within the United States.

Author information

1
University of Michigan, Ann Arbor, MI, USA.
2
Swedish Cancer Institute, Edmonds, WA, USA.
3
University of Washington/Fred Hutchinson Cancer Research Center, Seattle Cancer Care Alliance, Seattle, WA, USA.
4
Seattle Cancer Care Alliance, University of Washington, Seattle, WA, USA.
5
Cleveland Clinic Foundation, Cleveland, OH, USA.
6
Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, OH, USA.
7
Northwestern University, Chicago, IL, USA.
8
Wilmot Cancer Institute, University of Rochester Cancer Center, Rochester, NY, USA.
9
University Hospitals of Cleveland, Cleveland, OH, USA.
10
Division of Hematology and Hematologic Malignancies, University of Utah, Huntsman Cancer Institute, Salt Lake City, UT, USA.
11
City of Hope Medical Center, Duarte, CA, USA.
12
Department of Medicine, City of Hope, Duarte, CA, USA.
13
Columbia University, New York, NY, USA.
14
Center for Lymphoid Malignancies, Department of Medicine, Columbia University Medical Center, New York, NY, USA.
15
Rogel Cancer Center, University of Michigan, Ann Arbor, MI, USA.

Abstract

Intravascular large B-cell lymphoma (IVLBCL) is a rare entity, with a generally aggressive course that may vary based on geographic presentation. While a United States (US) registry study showed relatively good outcomes with IVLBCL, clinicopathological and treatment data were unavailable. We performed a detailed retrospective review of cases identified at 8 US medical centres, to improve understanding of IVLBCL and inform management. We compiled data retrieved via an Institutional Review Board-approved review of IVLBCL cases identified from 1999 to 2015 at nine academic institutions across the US. We characterized the cohort's clinical status at time of diagnosis, presenting diagnostic and clinical features of the disease, treatment modalities used and overall prognostic data. Our cohort consisted of 54 patients with varying degrees of clinical features. Adjusting for age, better performance status at presentation was associated with increased survival time for the patients diagnosed in vivo (hazard ratio: 2·12, 95% confidence interval 1·28, 3·53). Based on the data we have collected, it would appear that the time interval to diagnosis is a significant contributor to outcomes of patients with IVLBCL.

KEYWORDS:

B cells; diagnostic haematology; lymphomas

PMID:
31044423
DOI:
10.1111/bjh.15923

Supplemental Content

Full text links

Icon for Wiley
Loading ...
Support Center